Summit Therapeutics (NASDAQ:SMMT) shares spiked on Thursday, triggering a trading halt after Bloomberg News reported that ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

Merck & Co., Inc. (NYSE:MRK) ranks among the best set-it-and-forget-it stocks to buy. On June 27, TD Cowen maintained its ...

Merck (MRK) ended the recent trading session at $80.93, demonstrating a -1.77% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.83%. At the same time, ...

Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% ...

The stock's fall snapped a four-day winning streak.

Demand fell 1.4 per cent from the previous month in May, the statistics office said on July 4. Read more at straitstimes.com.

Merck’s stock fell 1.77% to $80.93 while the market gained, despite rising 5.26% over the past month. The company’s upcoming ...

The S&P 500 added 0.8% on Thursday, July 3, 2025, reaching a record closing high as a strong jobs report helped boost ...

A small study shows sensors embedded in a face mask appear to detect compounds linked to kidney disease. This is part of ...

Two new observational studies highlight the outsized burden of cancer associated with human papillomavirus (HPV) among both ...